23andMe logo

Antibody and Protein Engineering Summer Intern - 23andMe

View Company Profile
Job Title
Antibody and Protein Engineering Summer Intern
Job Location
South San Francisco, CA
Job Description

During our 10-week summer internship program, you’ll join our antibody & protein engineering team who, through a variety of techniques, focus their efforts on antibody candidates as therapeutics or critical reagents. You will have the opportunity to lead a cutting-edge technology development project related to therapeutic antibody discovery. You will also have the opportunity to gain valuable insights into the therapeutic drug discovery and development process in an industry setting. The dates for Cohort 1 will be June 5, 2023 - August 18, 2023; the dates for Cohort 2 will be June 20, 2023 - September 1, 2023.


Who We Are

Since 2006, 23andMe’s mission has been to help people access, understand, and benefit from the human genome. We are a group of passionate individuals pushing the boundaries of what’s possible to help turn genetic insight into better health and personal understanding.


What You'll Do

  • Apply novel technology, like nanopore sequencing, to 23andMe discovery & engineering platform
  • Utilize single cell sorting technology
  • Leverage molecular biology skills to support antibody discovery efforts
  • Present final findings at Therapeutics wide meeting with fellow interns
  • Communicate and collaborate with other colleagues effectively


What You’ll Bring

  • Pursuing a master’s or PhD degree in immunology, cell biology, biochemistry, or molecular biology or related field within 2 years of graduation
  • Strong communication skills
  • Molecular biology skills
  • Cell culture experience
  • Ability to work onsite 40 hours/week Monday-Friday in South San Francisco, CA
  • Authorization to work in the US
  • Please share with us why you're interested in this opportunity in a cover letter!


Strongly Preferred

  • Fluorescent activated cell sorting experience
  • Experience with nanopore technology
  • Experience in large scale sequence informatics and bioinformatic analysis


About Us

23andMe, headquartered in Sunnyvale, CA, is a leading consumer genetics and research company. Founded in 2006, the company’s mission is to help people access, understand, and benefit from the human genome. 23andMe has pioneered direct access to genetic information as the only company with multiple FDA authorizations for genetic health risk reports. The company has created the world’s largest crowdsourced platform for genetic research, with 80 percent of its customers electing to participate. The platform also powers the 23andMe Therapeutics group, currently pursuing drug discovery programs rooted in human genetics across a spectrum of disease areas, including oncology, respiratory, and cardiovascular diseases, in addition to other therapeutic areas. More information is available at www.23andMe.com.

At 23andMe, we value a diverse, inclusive workforce and we provide equal employment opportunity for all applicants and employees. All qualified applicants for employment will be considered without regard to an individual’s race, color, sex, gender identity, gender expression, religion, age, national origin or ancestry, citizenship, physical or mental disability, medical condition, family care status, marital status, domestic partner status, sexual orientation, genetic information, military or veteran status, or any other basis protected by federal, state or local laws.  If you are unable to submit your application because of incompatible assistive technology or a disability, please contact us at accommodations-ext@23andme.com. 23andMe will reasonably accommodate qualified individuals with disabilities to the extent required by applicable law.

Please note: 23andMe does not accept agency resumes and we are not responsible for any fees related to unsolicited resumes. Thank you.

23andMe Headquarters Location

Mountain View, CA

23andMe Company Size

Between 500 - 1,000 employees

23andMe Founded Year


23andMe Funding Rounds

  • Post Ipo Equity

    $250,000,000 USD

  • Series F

    $82,500,000 USD

  • Corporate Round

    $300,000,000 USD

  • Series F

    $250,000,000 USD

  • Grant

    $1,700,000 USD

  • Series E

    $115,000,000 USD

  • Grant

    $1,400,000 USD

  • Series D

    $50,000,000 USD

  • Series C

    $9,000,000 USD

  • Series C

    $22,220,289 USD

  • Series B

    $14,200,000 USD

  • Series B

    $13,600,000 USD

  • Series A

    $8,953,320 USD